The Therapeutic Role of Renin-Angiotensin System Blockers in Obesity- Related Renal Disorders
The Renin-Angiotensin System (RAS) is recognized as the main biological system involved in cardiovascular and hydroelectrolyte homeostasis. It is well established in literature that RAS blockers retard the progression of renal failure in type 1 [angiotensin converting enzyme (ACE) inhibitors]
and in type 2 [angiotensin type 1 receptor (AT1) antagonists] diabetes mellitus and in non-diabetic chronic kidney diseases. More recently, it was shown that newer therapeutic agents, the renin inhibitors, also exert renoprotective actions. Obesity is recognized as a proinflammatory state
often associated with kidney diseases. Recent publications have associated the RAS axis imbalance leading to a predominance of Angiotensin II effects with changes in adipokine levels and actions. In this context, the aim of the current review is to present current evidence on the potential
role of RAS blockers in modulating the interaction between adipokines and obesity-related renal disorders.
Keywords: Adipokines; angiotensin II; angiotensin-(1-7); chronic kidney disease; inflammation; obesity
Document Type: Research Article
Publication date: 01 February 2014
- Current Clinical Pharmacology publishes frontier reviews on all the latest advances in clinical pharmacology. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: pharmacokinetics; therapeutic trials; adverse drug reactions; drug interactions; drug metabolism; pharmacoepidemiology; and drug development. The journal is essential reading for all researchers in clinical pharmacology.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content